Sort
23,748 grants matching “melanoma”
Community Clinical Oncology Program
$400,119Northshore Univ Healthsystem Res Inst · U10 · FY2004 · CA
Project 2: Analyses of the human GBM microenvironment form clinical trial specimens treated with the oncolytic HSV, rQNestin34v.2
$400,081E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2023 · CA
Establishing the clinical utility of cell-free tumor DNA methylation profiling as a reliable liquid biopsy approach in brain tumors
$400,069Gelareh Zadeh · University Health Network · R01 · FY2023 · CA
A Novel Symbiotic Approach For Targeted Ovarian Cancer Therapy
$400,048Jogender Tushir-Singh · University Of Virginia · R01 · FY2019 · CA
Imaging Mitochondrial Redox States In Vivo by Hyperpolarized MR
$400,008Lin Z Li · University Of Pennsylvania · R01 · FY2012 · CA
Engineered TCR-T Cell Therapy Targeting Driver Mutations in NSCLC
$400,000Matthew James Spindler · Gigamune, Inc. · R43 · FY2021 · CA
High-throughput Label-free Biosensor Platform for Rapid Detection of Antigen-specific T Cells with Single Cell Resolution
$400,000Farshid Ghasemi · Weddell Technologies Llc · R43 · FY2021 · CA
University of New Mexico Cancer Center Support Grant
$400,000Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2019 · CA
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$400,000Jeffrey A Sosman · Vanderbilt University · R01 · FY2013 · FD
Development of polymeric synthetic biomaterial IP-001 to potentiate asystemic immunotherapy of hepatocellular carcinoma via thermal ablation
$400,000Siu Kit Lam · Immunophotonics, Inc. · R44 · FY2021 · CA
Bioengineering approaches to map mechanotransduction in the living cell
$400,000Ning Wang · Northeastern University · R01 · FY2025 · GM
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · AI
TOPIC 418 "HIGH THROUGHPUT SPATIALOMICS PROFILING FOR THICK TUMORTISSUES"
$400,000Alan Hauser · Arvetas Biosciences, Inc. · N43 · FY2021 · CA
Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis
$400,000Donald Davidson · Creative Biotherapeutics, Llc · R43 · FY2024 · CA
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · AI
Engineered TCR-T Cell Therapies Targeting Shared Tumor Associated Antigens
$400,000Matthew James Spindler · Gigamune, Inc. · R43 · FY2021 · CA
Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer
$400,000Robert Schickel · Nuago Therapeutics Inc · R42 · FY2025 · CA
Optimization of TIL Cell Manufacturing for Cancer Treatment
$400,000Soon Seog Jeong · Human Cell Co · R43 · FY2023 · CA
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · AI
Development of a novel pan-cancer CAR-T product against AML and Glioblastoma
$400,000David Soler · Kure. Ai, Inc. · R43 · FY2024 · CA
A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients
$400,000Aaron D Schuler · Syntrix Biosystems, Inc. · R44 · FY2024 · CA
A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
$400,000Aaron D Schuler · Syntrix Biosystems, Inc. · R44 · FY2023 · CA
Cancer Center Support Grant (CCSG)
$400,000George J Weiner · University Of Iowa · P30 · FY2016 · CA
A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S.
$400,000Michael J Shamblott · Morphogenesis, Inc. · R43 · FY2021 · CA
SIRPant Technology for anti-Cancer Immunity
$400,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2021 · CA